ArticleFrontiers in cellular and infection microbiology2025
Multi-biomarker score model for predicting fatal outcomes in severe fever with thrombocytopenia syndrome: a multicenter cohort study.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is a rapidly progressive disease with high mortality. This study aims to identify mortality risk factors in SFTS and create a prognostic model for early high-risk patient identification. Methods: A total of 301 SFTS patients were enrolled between May 2012 and July 2023 from nine clinical centers across the East China region. Using principal component analysis and cox regression, we identified independent risk factors for mortality and constructed the multi-biomarker score model (1 point was assigned when age ≥60 years, AST/ALT ratio ≥2.23, BUN ≥5.6 mmol/L, ALP ≥ 68 U/L, or ALB <33.3 g/L). Results: Of the 301 patients with SFTS, 57 (18.9%) experienced fatal outcomes during hospitalization. The risk of mortality escalated with each additional point on the multi-biomarker score, with a HR of 2.04 (95% CI, 1.60-2.61). Patients were stratified into low (0-1), intermediate (2-3), and high (4-5) risk groups based on their multi-biomarker scores. Notably, those in the high-risk category were at an over eightfold increased risk of mortality (HR, 8.59; 95% CI, 2.63-28.05). High scores (4-5) were also predictive of adverse outcomes, including secondary bacterial infection, meningitis, ICU admission, heart failure, respiratory failure, and renal failure. The receiver operating characteristic (ROC) curve analysis for the multi-biomarker score revealed an AUC of 0.769 (95% CI, 0.632-0.787), suggesting a cutoff value above 3 as the threshold for optimal discrimination. Conclusions: SFTS patients with more than three of the following criteria-age ≥60 years, AST/ALT ratio ≥2.23, BUN ≥5.6 mmol/L, ALP ≥68 U/L, or ALB <33.3 g/L-show a significantly elevated mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.